WO2016190852A1 - Compositions thérapeutiques comprenant des composés chromanyle, des variants et des analogues associés, et leurs utilisations - Google Patents

Compositions thérapeutiques comprenant des composés chromanyle, des variants et des analogues associés, et leurs utilisations Download PDF

Info

Publication number
WO2016190852A1
WO2016190852A1 PCT/US2015/032440 US2015032440W WO2016190852A1 WO 2016190852 A1 WO2016190852 A1 WO 2016190852A1 US 2015032440 W US2015032440 W US 2015032440W WO 2016190852 A1 WO2016190852 A1 WO 2016190852A1
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
group
absent
hydrogen
alkenyl
Prior art date
Application number
PCT/US2015/032440
Other languages
English (en)
Inventor
D. Travis Wilson
Original Assignee
Stealth Peptides International, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Peptides International, Inc. filed Critical Stealth Peptides International, Inc.
Priority to PCT/US2015/032440 priority Critical patent/WO2016190852A1/fr
Publication of WO2016190852A1 publication Critical patent/WO2016190852A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/66—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des méthodes et des compositions pour le traitement et/ou la prévention de maladies ou d'états pathologiques consistant à administrer des composés chromanyle, et/ou des dérivés, des analogues, des stéréoisomères, des tautomères, des solvates et des sels pharmaceutiquement acceptables de ceux-ci, d'origine naturelle ou artificielle, seuls ou en association avec un ou plusieurs agents actifs (par exemple un peptide aromatique-cationique). La présente technologie fournit des compositions associées à des peptides aromatiques-cationiques liés à des composés chromanyle ou à des dérivés, des analogues, des stéréoisomères, des tautomères, des solvates et des sels pharmaceutiquement acceptables de ceux-ci, et des utilisations de celles-ci. Dans certains modes de réalisation, le peptide aromatique-cationique comprend le D-Arg-2'6'-Dmt-Lys-Phe-NH2.
PCT/US2015/032440 2015-05-26 2015-05-26 Compositions thérapeutiques comprenant des composés chromanyle, des variants et des analogues associés, et leurs utilisations WO2016190852A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/US2015/032440 WO2016190852A1 (fr) 2015-05-26 2015-05-26 Compositions thérapeutiques comprenant des composés chromanyle, des variants et des analogues associés, et leurs utilisations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2015/032440 WO2016190852A1 (fr) 2015-05-26 2015-05-26 Compositions thérapeutiques comprenant des composés chromanyle, des variants et des analogues associés, et leurs utilisations

Publications (1)

Publication Number Publication Date
WO2016190852A1 true WO2016190852A1 (fr) 2016-12-01

Family

ID=57393576

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/032440 WO2016190852A1 (fr) 2015-05-26 2015-05-26 Compositions thérapeutiques comprenant des composés chromanyle, des variants et des analogues associés, et leurs utilisations

Country Status (1)

Country Link
WO (1) WO2016190852A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019070917A1 (fr) * 2017-10-03 2019-04-11 The Schepens Eye Research Institute, Inc. Composés et compositions pour inhiber la dégénérescence de l'épithélium pigmentaire rétinien et procédés les utilisant
WO2023023256A1 (fr) * 2021-08-18 2023-02-23 Oculogenex Inc. Transfert de gènes médié par aav pour une rétinopathie

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030187059A1 (en) * 2002-02-22 2003-10-02 Levin Robert M. Methods and compounds useful in inhibiting oxidative and/or free radical damage and in the treatment and prevention of disease
US20040259763A1 (en) * 2000-07-12 2004-12-23 Maria Koufaki Bifunctional agents possessing antioxidant and antiarrhythmic activity
US20060193797A1 (en) * 2005-02-25 2006-08-31 Galileo Pharmaceuticals, Inc Chroman derivatives as lipoxygenase inhibitors
WO2010106209A1 (fr) * 2009-03-20 2010-09-23 Consejo Superior De Investigaciones Científicas (Csic) Utilisation d'un composé pour le traitement d'une lésion produite par une reperfusion post-ischémique
US20110136898A1 (en) * 2008-08-05 2011-06-09 University College Cork, National University Of Ireland, Cork Treatment of retinal degeneration
US20110280805A1 (en) * 2008-10-31 2011-11-17 Neurodyn, Inc. Neurotoxic sterol glycosides
US20130158106A1 (en) * 2010-06-02 2013-06-20 The United States Of America As Represented By The Department Of Veteran Affairs Tocopherol derivatives and methods of use
US20130303436A1 (en) * 2012-12-06 2013-11-14 Stealth Peptides Internatioanl, Inc. Peptide therapeutics and methods for using same
WO2014011047A1 (fr) * 2012-07-12 2014-01-16 Khondrion B.V. Dérivés de chromanyle destinés au traitement de la maladie mitochondriale
WO2014022552A1 (fr) * 2012-08-02 2014-02-06 Stealth Peptides International, Inc. Methodes de traitement de l'atherosclerose

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040259763A1 (en) * 2000-07-12 2004-12-23 Maria Koufaki Bifunctional agents possessing antioxidant and antiarrhythmic activity
US20030187059A1 (en) * 2002-02-22 2003-10-02 Levin Robert M. Methods and compounds useful in inhibiting oxidative and/or free radical damage and in the treatment and prevention of disease
US20060193797A1 (en) * 2005-02-25 2006-08-31 Galileo Pharmaceuticals, Inc Chroman derivatives as lipoxygenase inhibitors
US20110136898A1 (en) * 2008-08-05 2011-06-09 University College Cork, National University Of Ireland, Cork Treatment of retinal degeneration
US20110280805A1 (en) * 2008-10-31 2011-11-17 Neurodyn, Inc. Neurotoxic sterol glycosides
WO2010106209A1 (fr) * 2009-03-20 2010-09-23 Consejo Superior De Investigaciones Científicas (Csic) Utilisation d'un composé pour le traitement d'une lésion produite par une reperfusion post-ischémique
US20130158106A1 (en) * 2010-06-02 2013-06-20 The United States Of America As Represented By The Department Of Veteran Affairs Tocopherol derivatives and methods of use
WO2014011047A1 (fr) * 2012-07-12 2014-01-16 Khondrion B.V. Dérivés de chromanyle destinés au traitement de la maladie mitochondriale
WO2014022552A1 (fr) * 2012-08-02 2014-02-06 Stealth Peptides International, Inc. Methodes de traitement de l'atherosclerose
US20130303436A1 (en) * 2012-12-06 2013-11-14 Stealth Peptides Internatioanl, Inc. Peptide therapeutics and methods for using same

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019070917A1 (fr) * 2017-10-03 2019-04-11 The Schepens Eye Research Institute, Inc. Composés et compositions pour inhiber la dégénérescence de l'épithélium pigmentaire rétinien et procédés les utilisant
US11260048B2 (en) 2017-10-03 2022-03-01 The Schepens Eye Research Institute, Inc. Compounds and compositions for inhibiting retinal pigment epithelium degeneration and methods using the same
WO2023023256A1 (fr) * 2021-08-18 2023-02-23 Oculogenex Inc. Transfert de gènes médié par aav pour une rétinopathie

Similar Documents

Publication Publication Date Title
US20190023738A1 (en) Therapeutic compositions including phenazine-3-one and phenothiazine-3-one derivatives and uses thereof
US10293020B2 (en) Peptide therapeutics and methods for using same
US20160199437A1 (en) Therapeutic compositions including iron chelators and uses thereof
US20180344814A1 (en) Peptide therapeutics and methods for using same
US11141456B2 (en) Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
WO2015183963A2 (fr) Compositions thérapeutiques comprenant des parabenzoquinones à activité redox et leurs utilisations
WO2016200364A1 (fr) Compositions thérapeutiques contenant des composés skq et leurs utilisations
WO2016195663A1 (fr) Compositions thérapeutiques comprenant bpm 31510, leurs variants et leurs analogues, et leurs utilisations
WO2016004093A2 (fr) Compositions thérapeutiques comprenant des inhibiteurs de la galectine-3 et utilisations de celles-ci
US20180354991A1 (en) Therapeutic compositions including gramicidin s peptidyl conjugates or imidazole-substituted fatty acids, variants thereof and uses thereof
US20170182117A1 (en) Therapeutic compositions including therapeutic small molecules and uses thereof
WO2015183985A2 (fr) Compositions thérapeutiques comprenant des naphthoquinones et leurs utilisations
WO2015183984A2 (fr) Compositions thérapeutiques contenant un tocophérol et leurs utilisations
US20160279255A1 (en) THERAPEUTIC COMPOSITIONS INCLUDING MODULATORS OF deltaPKC AND/OR epsilonPKC, AND USES THEREOF
WO2016190852A1 (fr) Compositions thérapeutiques comprenant des composés chromanyle, des variants et des analogues associés, et leurs utilisations
US20180042983A1 (en) Therapeutic compositions including mitochondrial fission inhibitor peptides, variants thereof, and methods of using the same
WO2016144352A2 (fr) Compositions thérapeutiques comprenant des composés acrylamido ou des composés maléimide à substitution phényle, variants et méthodes d'utilisation associés
US20240108740A1 (en) Therapeutic compositions including spn10 and uses thereof
WO2015183970A1 (fr) Compositions thérapeutiques contenant un flavonoïde et leurs utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15893493

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 23/02/2018)

122 Ep: pct application non-entry in european phase

Ref document number: 15893493

Country of ref document: EP

Kind code of ref document: A1